Found: 7
Select item for more details and to access through your institution.
Letter: SPOSIB SB2—a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2.
- Published in:
- 2019
- By:
- Publication type:
- Letter to the Editor
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease.
- Published in:
- Journal of Gastroenterology & Hepatology, 2023, v. 38, n. 9, p. 1503, doi. 10.1111/jgh.16208
- By:
- Publication type:
- Article
SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501.
- Published in:
- Journal of Gastroenterology & Hepatology, 2021, v. 36, n. 11, p. 3041, doi. 10.1111/jgh.15590
- By:
- Publication type:
- Article
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease.
- Published in:
- Journal of Gastroenterology & Hepatology, 2021, v. 36, n. 1, p. 105, doi. 10.1111/jgh.15107
- By:
- Publication type:
- Article
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
- Published in:
- Drugs & Aging, 2020, v. 37, n. 5, p. 383, doi. 10.1007/s40266-020-00744-3
- By:
- Publication type:
- Article
Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease.
- Published in:
- Journal of Crohn's & Colitis, 2019, v. 13, n. 2, p. 209, doi. 10.1093/ecco-jcc/jjy156
- By:
- Publication type:
- Article
An Optimized Terpene Profile for a New Medical Cannabis Oil.
- Published in:
- Pharmaceutics, 2022, v. 14, n. 2, p. 298, doi. 10.3390/pharmaceutics14020298
- By:
- Publication type:
- Article